Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis: A case report

Chinese Medical Sciences Journal

Volumn 28, Issue 2, 2013, Pages 127-128

  Xie, Jing ^a   Zhang, Xiang ^a   Fang, Bao Zhi ^a   He, Guang Sheng ^a   Zhao, Yun ^a   Wu, De Pei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

chronic myeloid leukemia; imatinib; imatinib resistent; mammalian target of rapamycin; rapamycin

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ADULT; ARTICLE; BLAST CELL CRISIS; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG DOSE INCREASE; FUSION GENE; HUMAN; IN VITRO STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REMISSION; TREATMENT DURATION;

ADULT; BENZAMIDES; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; SIROLIMUS;

EID: 84880538079     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1001-9294(13)60036-X     Document Type: Article

References (10)

1. M Deininger, E Buchdunger, BJ Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653
2. C Walz, M Sattler Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) Crit Rev Oncol Hematol 57 2006 145 164
3. A Burchert, Y Wang, D Cai et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development Leukemia 19 2005 1774 1782
4. DJ Barnes, JV Melo Management of chronic myeloid leukemia: targets for molecular therapy Semin Hematol 40 2003 34 49
5. M Hidalgo, EK Rowinsky The rapamycin-sensitive transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686
6. K Podsypanina, RT Lee, C Politis et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci U S A 98 2001 10320 10325
7. Y Yamamoto-Yamaguchi, J Okabe-Kado, T Kasukabe et al. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors Exp Hematol 29 2001 582 588
8. C Ly, AF Arechiga, JV Melo et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin Cancer Res 63 2003 5716 5722
9. MG Mohi, C Boulton, TL Gu et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs PNAS 101 2004 3130 3135
10. M Mayerhofer, A Boehm, KJ Aichberger et al. In vitro and in vivo antileukemic effects of the mTOR-targeting drugs rapamycin in patients with imatinib-resistant CML Blood 2005 106 abstract 4834.